Our Vision.

Cancer is a major cause of morbidity and mortality, with an estimated 18.1 million newly diagnosed patients per year and 9.6 million cancer-related deaths in 2018 (WHO, International Agency for Research on Cancer, September 12th, 2018). Although new therapies have seen substantial success in treating this widespread disease, difficult issues remain, such as the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy.

In an effort to contribute to the global fight against cancer, OncoOne leverages our proprietary drug development know-how to create first-in-class, novel, and highly potent therapeutics in order to treat underserved patients suffering from solid tumor cancers.

As a business model, OncoOne intends to ensure that we strive to apply state-of-the-art technologies and the highest possible quality standards in order to establish a successful and continuously evolving life science company.

Our Founders & Management Board.

OncoOne was founded in June 2018 by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl. The founders have a long history in industrial drug development and oncology research. Each member of the management team has successfully contributed to the development of GMP grade drug substances, patents and scientific publications. Our management team is comprised of professionals experienced in science management, leading networks of innovation by external collaborations and performing first-class in-house laboratory work.

This team discovered that the macrophage migration inhibitory factory (or MIF) oxidized at sites of inflammation, such as a tumor, arthritic joint, or asthmatic lung, and is working on first- and best-in-class therapeutics to target this well-researched cytokine.

Randolf Kerschbaumer, PhD.

Co-Founder & Chief Executive Officer

Randolf has more than 20 years of experience in academic and big pharma R&D and has detailed knowledge of the entire drug development process, from early drug screening to clinical development. Randolf received a PhD in Biotechnology from the Vienna University of Natural Resources and Life Sciences (BOKU). He started his professional career at Baxter BioScience and held various senior leading positions in research and development of therapeutics for cancer, inflammation and hematologic disorders. Most recently, he led the Oncology Research department at Shire. Additionally, he teaches “Industrial Drug Development” at the University of Natural Resources and Life Sciences (BOKU), Vienna.

Randolf applies his knowledge and network of talented professionals and institutions regionally and globally to optimize first-in-class drug development. His intellectual curiosity, love for science and strong entrepreneurial personality enables Randolf to link science with corporate strategies.

Michael Thiele, PhD.

Co-Founder & Chief Scientific Officer

Michael is a renowned expert in immunology, tumor biology, biomarkers and the development of biologics. Michael obtained his PhD in Biology at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Germany and started his professional career at Baxter BioScience. During his career at Baxter, Baxalta and Shire, Michael was leading a network of innovation with contract research organizations (CROs), key opinion leaders and academic institutions, which led to the discovery of new therapeutic targets. Before founding OncoOne Michael was heading the Department of Cell Biology in Oncology Research, R&D, at Shire.

His strong expertise in oncology and connection to an international scientific network enables Michael to provide the professional excellence to establish and coordinate a strong alliance with experts. He is excels in developing innovative cancer therapeutics in a flexible and professional environment.

Alexander Schinagl, PhD.

Co-Founder & Chief Technology Officer

Alexander has a broad knowledge of molecular biology, biochemistry and cell biology techniques in the field of oncology and inflammation. He received a PhD in Biotechnology from the Vienna University of Natural Resources and Life Sciences (BOKU) in an industrial collaboration with Baxter and Baxalta Innovations GmbH. Alexander started his career as a master’s student at Baxter BioScience in 2009 with a focus on assay design for drug characterization. In his position as Supervisor, Alexander was leading and training laboratory technicians in a biosafety regulated environment in the department of Oncology Research.

Alexander´s passion for science, creativity and attention to detail enables him to link scientific innovation with drug development. He is excited to explore novel cancer therapeutics in an innovative and creative environment.

Brent Meadows.

OncoOne US Co-Founder and Chief Business Officer

Brent has more than 25 years of experience in both large pharmaceutical and small biotech companies primarily focused on oncology drug development, launch marketing, and both in- and out-licensing partnership deals. Brent started his career as a US Army officer leading successful teams in Germany. His pharmaceutical career started at Johnson & Johnson where he established relationships with some of the world’s top oncologists and was a key leader on J&J’s first global launch team. Brent led Healthcare Provider marketing and Key Opinion Leader partnerships for ERBITUX® (Cetuximab) while at Bristol-Myers Squibb before joining AVEO Oncology as their first commercial hire and Co-Program Executive for tivozanib (FOTIVDA®) leading to the EMEA approval and $1.4 billion partnership with Astellas. Brent has also held strategic pipeline commercialization leadership roles at Regeneron, Baxalta, and Biogen.

Brent received his Bachelor’s of Science in Business Administration from the University of Richmond and his Master’s of Business Administration in Entrepreneurial Studies from Babson College. Brent brings both his expertise in drug development strategy and commercialization as well as his extensive network of clinical and industry experts to OncoOne.

Our Team.

Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics. As our company continues to grow, we are looking for individuals with a passion for science who want to achieve something extraordinary.